Invention Grant
- Patent Title: Biomarkers for inflammatory bowel disease
-
Application No.: US15642252Application Date: 2017-07-05
-
Publication No.: US11041206B2Publication Date: 2021-06-22
- Inventor: Paul A. Lyons , Kenneth G. C. Smith , Eoin F. McKinney , Daniele Biasci , James Lee
- Applicant: Cambridge Enterprise Limited
- Applicant Address: GB Cambridge
- Assignee: Cambridge Enterprise Limited
- Current Assignee: Cambridge Enterprise Limited
- Current Assignee Address: GB Cambridge
- Agency: Nutter McClennen & Fish LLP
- Priority: GB1611738 20160705
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6883 ; G16B25/00

Abstract:
The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.
Public/Granted literature
- US20180010187A1 Biomarkers for Inflammatory Bowel Disease Public/Granted day:2018-01-11
Information query